Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_1125_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
02.09.2026
Размер:
20 Мб
Скачать
6 Anal Fistula
147
sometimes develop more typical Crohn’s fi stula in the future. Overly aggressive treatment of fi stulas with repeated injury to the sphincter will lead to incontinence. Again, the emphasis is on relieving symptoms, not complete cure of the fi stula. For a symptomatic fi stula, placing a seton can be a good choice. The ideal setting for attempts at cure is fi stulas that are either intersphincteric or low transsphincteric fi stulas. The Crohn’s disease should be well controlled and ideally not located in the anal canal or rectum. Once a decision has been made to attempt a curative surgery, all of the options for fi stulas are viable. There is no high-level evidence to help sepa­rate out the various options.
6.8.3 Anal Fistula and Carcinoma
Long-standing chronic infl ammation in the region of the anal glands is believed by some to lead to malignant degeneration. Immunohistochemical staining has revealed that the origin of these cancers may be from the rectal mucosa rather than the anal glands in one small series [ 113 ]. The presence of tumor mass, bloody discharge, and mucin secretion is suggestive of the presence of an underlying tumor [ 114 ]. A nationwide pathology database in the Netherlands identifi ed only four cases of malignant transformation of a fi stula, and all occurred in individuals with Crohn’s disease [ 115 ]. Both adenocarcinoma and squamous cell carcinomas have been reported. Ky and coworkers related 7 patients with carcinoma arising in anorectal fi stulas associated with Crohn’s disease and identifi ed 33 more in the literature [ 116 ]. Millar described three cases of villous tumors arising in anal fi stula [ 117 ]. Differential diagnosis includes anal canal carcinoma with fi stula, carcinoma of the rectum with fi stula, hidradenitis suppurativa with malignant degeneration, and carcinoma arising in an anal canal duct [ 118 , 119 ] .

References

1. Parks AG, Gordon PH, Hardcastle JD. A classifi cation of fi stula-in-ano. Br J Surg. 1976;
63(1):1–12.
2. Cirocco WC, Reilly JC. Challenging the predictive accuracy of Goodsall’s rule for anal fi stu-
lae. Dis Colon Rectum. 1992;35(6):537–42.
3. Stoker J, Rociu E, Wiersma TG, et al. Image of anorectal disease. Br J Surg. 2000;
87(1):10–27.
4. Parks AG, Gordon PH. Perineal fi stula of intra-abdominal or intrapelvic origin simulating
fi stula-in-ano: report of seven cases. Dis Colon Rectum. 1976;19:500–6.
5. Gold DM, Bartram CI, Halligan S, et al. Three-dimensional endoanal sonography in
assessing anal canal injury. Br J Surg. 1999;86(3):365–70.
6. Saclarides TJ. Anorectal ultrasound. In: Machi J, Staren ED, editors. Ultrasound for
surgeons. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
7. Choen S, Burnett S, Bartram CI, et al. Comparison between anal endosonography and digital
examination in the evaluation of anal fi stulae. Br J Surg. 1991;78(4):445–7.
8. Cataldo PA, Senagore A, Luchtefeld MA. Intrarectal ultrasound in the evaluation of perirectal
abscess. Dis Colon Rectum. 1993;36:554–8.
148
9. Cheong DMO, Nogueras JJ, Wexner SD, Jagelman DG. Anal endosonography for recurrent anal
fi stulas: image enhancement with hydrogen peroxide. Dis Colon Rectum. 1993;36:1158–60.
10. Buchanan GN, Bartram CI, Williams AB, et al. Value of hydrogen peroxide enhancement of
three-dimensional endoanal ultrasound in fi stula-in-ano. Dis Colon Rectum. 2005;48(1): 141–7.
11. Kim ML. Transrectal ultrasonography of anorectal diseases: advantages and disadvantages.
Ultrasonograpy. 2015;34:19–31.
12. Belliveau P, Thomson JP, Prks AG. Fistula-in-ano. A manometric study. Dis Colon Rectum.
1983;26(3):152–4.
13. Hussain SM, Stoker J, Schouten WR, et al. Fistula in ano: endoanal sonography versus endoanal
MR imaging in classifi cation. Radiology. 1996;200(2):475–81.
14. de Souza NM, Gilderdale DJ, Coutts GA, et al. MRI of fi stula-in-ano: a comparison of endoanal
coil with external phased array coil techniques. J Comput Assist Tomogr. 1998;22(3): 357–63.
15. Buchanan GN, Williams AM, Bartram CI, et al. Potential clinical implications of directions of a
trans-sphincteric anal fi stula track. Br J Surg. 2003;90(10):1250–5.
16. Sahni VA, Ahmad R, Burling D. Which method is best for imaging of perianal fi stula? Abdom
Imaging. 2008;33:26–30.
17. Lengyel AJ, Hurst NG, Williams JG. Pre-operative assessment of anal fi stulas using endoanal
ultrasound. Colorectal Dis. 2002;4(6):436–40.
18. Kronborg O. To lay open or excise a fi stula-in-ano: a randomized trial. Br J Surg. 1985;72(12):970.
19. Ritchie RD, Sackier JM, Hodde JP. Incontinence rates after cutting seton treatment for anal fi s-
tula. Colorectal Dis. 2008;11:564–71.
20. Elting AWX. The treatment of fi stula in ano: with special reference to the Whitehead Operation.
Ann Surg. 1912;56(5):744–52.
21. Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn’s disease with metronida-
zole. Gastroenterology. 1980;79(2):357–65.
22. Bleier JI, Moloo H, Goldberg SM. Ligation of the intersphincteric fi stula tract: an effective new
technique for complex fi stulas. Dis Colon Rectum. 2010;53(1):43–6.
23. Parks AG, Stitz RW. The treatment of high fi stula-in-ano. Dis Colon Rectum. 1976;19:
487–99.
24. William JG, MacLeod CA, Rothenberger DA, et al. Seton treatment of high anal fi stulae. Br J
Surg. 1991;78(10):1159–61.
25. Kuypers HC. Use of the seton in the treatment of extrasphincteric anal fi stula. Dis Colon Rectum.
1984;27(2):109–10.
26. Ritchie RD, Sackier JM, Hodde JP. Incontinence rates after cutting seton treatment for anal fi s-
tula. Colorectal Dis. 2009;11(6):564–71.
27. Browsing GGP, Parks AG. Postal repair for neuropathic fecal incontinence: correlation of clini-
cal result and anal canal pressure. Br J Surg. 1983;70:101–4.
28. Tidrick R, Warner E. Fibrin fi xation of skin transplants. Surgery. 1944;15:90–5.
29. Hjortrup A, Moesgaard F, Kjaergard J. Fibrin adhesive in the treatment of perineal fi stulas. Dis
Colon Rectum. 1991;34(9):752–4.
30. Venkatesh KS, Ramanujam P. Fibrin glue application in the treatment of recurrent anorectal fi s-
tulas. Dis Colon Rectum. 1999;42(9):1136–9.
31. Cintron JR, Park JJ, Orsay CP, Pearl RK, Nelson RL, Abcarian H. Repair of fi stulas-in-ano using
autologous fi brin tissue adhesive. Dis Colon Rectum. 1999;42(5):607–13.
32. Cintron JR, Park JJ, Orsay CP, Pearl RK, Nelson RL, Sone JH, et al. Repair of fi stulas-in-ano
using fi brin adhesive: long-term follow-up. Dis Colon Rectum. 2000;43(7):944–9. discussion 949–50.
33. Sentovich SM. Fibrin glue for all anal fi stulas. J Gastrointest Surg. 2001;5(2):158–61.
M. Luchtefeld and T. Jalouta
6 Anal Fistula
34. Lindsey I, Smilgin-Humphreys MM, Cunningham C, Mortensen NJ, George BD. A random-
ized, controlled trial of fi brin glue vs. conventional treatment for anal fi stula. Dis Colon Rectum. 2002;45(12):1608–15.
35. Chan KM, Lau CW, Lai KK, Auyeung MC, Ho LS, Luk HT, et al. Preliminary results of
using a commercial fi brin sealant in the treatment of fi stula-in-ano. J R Coll Surg Edinb. 2002;47(1):407–10.
36. Sentovich SM. Fibrin glue for anal fi stulas: long-term results. Dis Colon Rectum.
2003;46(4):498–502.
37. Buchanan GN, Bartram CI, Phillips RK, Gould SW, Halligan S, Rockall TA, et al. Effi cacy
of fi brin sealant in the management of complex anal fi stula: a prospective trial. Dis Colon Rectum. 2003;46(9):1167–74.
38. Vitton V, Gasmi M, Barthet M, Desjeux A, Orsoni P, Grimaud JC. Long-term healing of
Crohn’s anal fi stulas with fi brin glue injection. Aliment Pharmacol Ther. 2005;21(12): 1453–7.
39. Witte ME, Klaase JM, Gerritsen JJ, Kummer EW. Fibrin glue treatment for simple and
complex anal fi stulas. Hepatogastroenterology. 2007;54(76):1071–3.
40. Hammond TM, Porrett TR, Scott SM, Williams NS, Lunniss PJ. Management of idiopathic
anal fi stula using cross-linked collagen: a prospective phase 1 study. Colorectal Dis. 2011; 13(1):94–104.
41. Maralcan G, Baskonus I, Gokalp A, Borazan E, Balk A. Long-term results in the treatment of
fi stula-in-ano with fi brin glue: a prospective study. J Korean Surg Soc. 2011;81(3):169–75.
42. de Oca J, Millan M, Jimenez A, Golda T, Biondo S. Long-term results of surgery plus fi brin
sealant for anal fi stula. Colorectal Dis. 2012;14(1):e12–5.
43. Herreros MD, Garcia-Arranz M, Guadalajara H, De-La-Quintana P, Garcia-Olmo D, FATT
Collaborative Group. Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fi stulas: a phase III randomized clinical trial (FATT1: fi s­tula Advanced Therapy Trial 1) and long-term evaluation. Dis Colon Rectum. 2012;55(7): 762–72.
44. Maralcan G, Baskonus I, Aybasti N, Gokalp A. The use of fi brin glue in the treatment of
fi stula- in-ano: a prospective study. Surg Today. 2006;36(2):166–70.
45. Abel ME, Chiu YS, Russell TR, et al. Autologous fi brin glue in the treatment of rectovaginal
and complex fi stulas. Dis Colon Rectum. 1993;36(5):447–9.
46. Buchanan GN, Bartram CI, Phillips RK, et al. Effi cacy of fi brin sealant in the management of
complex anal fi stula: a prospective trial. Dis Colon Rectum. 2003;46(9):1174.
47. Chung W, Kazemi P, Ko D, Sun C, Brown CJ, Raval M, et al. Anal fi stula plug and fi brin glue
versus conventional treatment in repair of complex anal fi stulas. Am J Surg. 2009;197(5): 604–8.
48. Dubsky PC, Stift A, Friedl J, Teleky B, Herbst F. Endorectal advancement fl aps in the treat-
ment of high anal fi stula of cryptoglandular origin: full-thickness vs. mucosal-rectum fl aps. Dis Colon Rectum. 2008;51(6):852–7.
49. Golub RW, Wise Jr WE, Kerner BA, Khanduja KS, Aguilar PS, Golub RW, Wise Jr WE,
Kerner BA, Khanduja KS, Aguilar PS. Endorectal mucosal advancement fl ap: the preferred method for complex cryptoglandular fi stula-in-ano. J Gastrointest Surg. 1997;1(5):487–91.
50. Zbar AP. Experience with staged mucosal advancement anoplasty for high trans-sphincteric
fi stula-in ano. West Indian Med J. 2007;56:446–50.
51. Mitalas LE, Dwarkasing RS, Verhaaren R, Zimmerman DD, Schouten WR. Is the outcome of
transanal advancement fl ap repair affected by the complexity of high transsphincteric fi stu­las? Dis Colon Rectum. 2011;54(7):857–62.
52. Mitalas LE, Gosselink MP, Oom DM, Zimmerman DD, Schouten WR. Required length of
follow-up after transanal advancement fl ap repair of high transsphincteric fi stulas. Colorectal Dis. 2009;11(7):726–8.
53. Ortiz H, Marzo M, de Miguel M, Ciga MA, Oteiza F, Armendariz P. Length of follow-up
stulotomy and fi stulectomy associated with endorectal advancement fl ap repair for
after fi fi stula in ano. Br J Surg. 2008;95(4):484–7.
149
150
54. Ortiz H, Marzo J, Ciga MA, Oteiza F, Armendariz P, de Miguel M. Randomized clinical trial
of anal fi stula plug versus endorectal advancement fl ap for the treatment of high cryptoglan­dular fi stula in ano. Br J Surg. 2009;96(6):608–12.
55. Perez F, Arroyo A, Serrano P, Sanchez A, Candela F, Perez MT, et al. Randomized clinical
and manometric study of advancement fl ap versus fi stulotomy with sphincter reconstruction in the management of complex fi stula-in-ano. Am J Surg. 2006;192(1):34–40.
56. Schouten WR, Zimmerman DD, Briel JW. Transanal advancement fl ap repair of
transsphincteric fi stulas. Dis Colon Rectum. 1999;42(11):1419–22. discussion 22–3.
57. van Koperen PJ, Wind J, Bemelman WA, Slors JF. Fibrin glue and transanal rectal advance-
ment fl ap for high transsphincteric perianal fi stulas; is there any advantage? Int J Colorectal Dis. 2008;23(7):697–701.
58. Wang JY, Garcia-Aguilar J, Sternberg JA, Abel ME, Varma MG. Treatment of transsphinc-
teric anal fi stulas: are fi stula plugs an acceptable alternative? Dis Colon Rectum. 2009;52(4): 692–7.
59. Christoforidis D, Pieh MC, Madoff RD, Mellgren AF. Treatment of transsphincteric anal
fi stulas by endorectal advancement fl ap or collagen fi stula plug: a comparative study. Dis Colon Rectum. 2009;52(1):18–22.
60. Uribe N, Millán M, Minguez M, Ballester C, Asencio F, Sanchiz V, Esclapez P, del Castillo
JR. Clinical and manometric results of endorectal advancement fl aps for complex anal fi stula. Int J Colorectal Dis. 2007;22:259–64.
61. Abbas MA, Lemus-Rangel R, Hamadani A. Long-term outcome of endorectal advancement
fl ap for complex anorectal fi stulae. Am Surg. 2008;74:921–4.
62. Mizrahi N, Wexner SD, Zmora O, Da Silva G, Efron J, Weiss EG, et al. Endorectal advance-
ment fl ap: are there predictors of failure? Dis Colon Rectum. 2002;45(12):1616–21.
63. Abbas MA, Jackson CH, Haigh PI. Predictors of outcome for anal fi stula surgery. Arch Surg.
2011;146(9):1011–6.
64. Buchbery B, Masoomi H, Cgoi J, et al. A tale of two (anal fi stula) plugs: is there a difference
in short-term outcomes? Am Surg. 2010;76(10):1150–3.
65. Grimaud JC, Munoz-Bongrand N, Siproudhis L, et al. Fibrin glue is effective healing perianal
fi stulas in patients with Crohn’s disease. Gastroenterology. 2010;138(7):2275–81. 2281.el.
66. De la Portilla F, Rada R, Jiménez-Rodríguez R, et al. Evaluation of a new synthetic plug in
the treatment of anal fi stulas: results of a pilot study. Dis Colon Rectum. 2011;54(11): 1419–22.
67. Heydari A, Attina G, Merolla E, et al. Treatment of anal fi stulas with GORE BIO-A fi stula
plug. Poster session presented at: 6th scientifi c & annual meeting of the European Society of Coloproctology; 2011 Sept 21–24; Copenhagen, Denmark; 2011.
68. Ratto C, Litta F, Parello A, et al. Gore Bio-A® Fistula Plug: a newsphincter-sparing proce-
dure for complex anal fi stula. Colorectal Dis. 2012;14(5):e264–9.
69. Ommer A, Herold A, Joos A, et al. Gore BioA Fistula Plug in the treatment of high anal
fi stulas—initial results from a German multicenter- study. Ger Med Sci. 2012;10:13.
70. Johnson EK, Gaw JU, Armstrong DN. Effi cacy of anal fi stula plug vs. fi brin glue in closure
of anorectal fi stulas. Dis Colon Rectum. 2006;49:371–6.
71. Champagne BJ, O’Connor LM, Ferguson M, Orangio GR, Schertzer ME, Armstrong
DN. Effi cacy of anal fi stula plug in closure of cryptoglandular fi stulas: long term follow- up. Dis Colon Rectum. 2006;49:1817–21.
72. O’Connor L, Champagne BJ, Ferguson MA, Orangio GR, Schertzer ME, Armstrong
DN. Effi cacy of anal fi stula plug in closure of Crohn’s anorectal fi stulas. Dis Colon Rectum. 2006;49:1569–73.
73. Ellis CN. Bioprosthetic plugs for complex anal fi stulas: an early experience. J Surg Educ.
2007;64:36–40.
74. Safar B, Jobanputra S, Sands D, Weiss EG, Nogueras JJ, Wexner SD. Anal fi stula plug: initial
experience and outcomes. Dis Colon Rectum. 2009;52:248–52.
M. Luchtefeld and T. Jalouta
6 Anal Fistula
75. Lawes DA, Efron JE, Abbas M, Heppell J, Young-Fadok TM. Early experience with the
bioabsorbable anal fi stula plug. World J Surg. 2008;32:1157–9.
76. El-Gazzaz G, Zutshi M, Hull T. A retrospective review of chronic anal fi stulae treated by anal
fi stulae plug. Colorectal Dis. 2010;12:442–7.
77. Rojanasakul A, Parranaarun J, Sahakirungruaung C, et al. Total anal sphincter saving tech-
nique for fi stula-in-ano; the ligation of intersphincteric fi stula tract. J Med Assoc Thai. 2007;90(3):581–6.
78. Rojanasakul A. LIFT procedure: a simplifi ed technique for fi stula-in- ano. Tech Coloproctol.
2009;13(3):237–40. doi:
79. Liu WY, Aboulian A, Kaji AH, Kumar RR. Long-term results of ligation of intersphincteric
fi stula tract (LIFT) for fi stula-in-ano. Dis Colon Rectum. 2013;56(3):343–7.
80. van Onkelen RS, Gosselink MP, Schouten WR. Is it possible to improve the outcome of
transanal advancement fl ap repair for high transsphincteric fi stulas by additional ligation of the intersphincteric fi stula tract? Dis Colon Rectum. 2012;55(2):153–6.
81. Ooi K, Skinner I, Croxford M, et al. Managing fi stula-in-ano with ligation of the intersphincteric
fi stula tract procedure: the Western Hospital experience. Colorectal Dis. 2012;14(5):599–603.
82. Aboulian A, Kaji AH, Kumar RR. Early result of ligation of the intersphincteric fi stula tract for
fi stula-in-ano. Dis Colon Rectum. 2011;54(3):289–92.
83. Shanwani A, Nor AM, Amri N. Ligation of the intersphincteric fi stula tract (LIFT):
a sphincter- saving technique for fi stula-in-ano. Dis Colon Rectum. 2010;53(1):39–42.
84. Vergara-Fernandez O, Espino-Urbina LA. Ligation of intersphincteric fi stula tract: what is the
evidence in a review? World J Gastroenterol. 2013;19(40):6805–13.
85. Leng Q, Jin H-Y. Anal fi stula plug vs mucosa advancement fl ap in complex fi stula-in-ano: a
meta-analysis. World J Gastrointest Surg. 2012;4(11):256–61. ISSN 1948-9366.
86. Mushaya C, Bartlett L. Ligation of intersphincteric fi stula tract compared with advancement
fl ap for complex anorectal fi stulas requiring initial seton drainage. Am J Surg. 2012;204:283–9.
87. Hanley PH. Conservative surgical correction of horseshoe abscess and fi stula. Dis Colon Rectum.
1965;8(5):364–8.
88. Hanley PH, Ray JE, Pennington EE, et al. Fistula-in-ano: a ten-year follow-up study of horseshoe-
abscess fi stula-in-ano. Dis Colon Rectum. 1976;19(6):505–15.
89. Van Tets WF, Kuijpers HC. Continence disorders after anal fi stulotomy. Dis Colon Rectum.
1994;37:1194–7.
90. Westerterp M, Volkers NA, Poolman RW, van Tets WF. Anal fi stulotomy between Skylla and
Charybdis. Colorectal Dis. 2003;5:549–55.
91. Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum.
1993;36(1):77–97.
92. Vaizey CJ, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal incontinence
grading systems. Gut. 1999;44(1):77–80.
93. Lunniss PJ, Kamm MA, Phillips RKS. Factors affecting continence after surgery for anal fi stula.
Br J Surg. 1994;81:1382–5.
94. Toyonaga T, Matsushima M, Kiriu T, Sogawa N, Kanyama H, Matsumura N, et al. Factors
affecting continence after fi stulotomy for intersphincteric fi stula-in-ano. Int J Colorectal Dis. 2007;22(9):1071–5.
95. Cohen Z, McLeod RS. Perianal Crohn’s disease. Gastroenterol Clin North Am.
1987;16(1):175–89.
96. Guy-Grand D, DiSanto JP, Henchoz P, Malassis-Seris M, Vassalli P. Small bowel enteropa-
thy: role of intraepithelial lymphocytes and of cytokines (IL-12, IFN-gamma, TNF) in the induction of cell death and renewal. Eur J Immunol. 1998;28:730–44.
97. Ng SC, Plamondon S, Gupta A, Burling D, Kamm MA. Prospective assessment of the effect
on quality of life of antitumour necrosis factor therapy for perineal Crohn’s fi stulas. Aliment Pharmacol Ther. 2009;30:757–66.
10.1007/s10151-009-0522-2 . Epub 2009 Jul 28.
151
152
98. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infl iximab maintenance treatment
reduces hospitalizations, surgeries, and procedures in fi stulizing Crohn’s disease. Gastroenterology. 2005;128:862–9.
99. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors.
Gastroenterology. 2000;119:1148–57.
100. Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour
necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn’s disease. Gut. 1997;40:470–4.
101. Kornbluth A. Infl iximab approved for use in Crohn’s disease: a report on the FDA GI
advisory committee conference. Infl amm Bowel Dis. 1998;4(4):328–9.
102. Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in infl amma-
tory bowel disease. World J Gastroenterol. 2009;15:2067–73.
103. Present DH, Rutgeerts P, Targan S, Hanauer S, Mayer L, van Hogezand RA, Podolsky D,
Sands B, Braakman T, DeWoody KL, Schaible TF, van Deventer SJH. Infl iximab for the treatment of fi stulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–405.
104. Malesci A, Angelucci E, Bonifacio C, Sociale O, Omodei P, Repici A, et al. Closure of peri-
anal fi stula using adalimumab in a Crohn’s disease patient naive to antitumor necrosis factor alpha antibodies. Infl amm Bowel Dis. 2009;15:814–5.
105. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human
anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–33.
106. Rizzello F, Gionchetti P, Tambasco R, Brugnera R, Straforini G, Calabrese C, et al.
Adalimumab in the treatment of active luminal and perianal Crohn’s disease: a single center experience in 100 patients. Gastroenterology. 2009;136:A-177.
107. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn’s disease with 6-mercaptopurin.
A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981–7.
108. Ochsenkühn T, Göke B, Sackmann M. Combining infl iximab with 6 mercaptopurine/azathio-
prine for fi stula therapy in Crohn’s disease. Am J Gastroenterol. 2002;97(8):2022–5.
109. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn’s dis-
ease: a meta analysis. Ann Intern Med. 1995;122:132–42.
110. Sartor RB. Current theories in the etiology of Crohn’s disease. Mt Sinai Newsl. 1995;2:2–6.
111. West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA,
Kuipers EJ. Clinical and endosonographic effect of ciprofl oxacin on the treatment of perianal fi stulae in Crohn’s disease with infl iximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20(11–12):1329–36.
112. Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn’s disease with
metronidazole. Gastroenterology. 1987;79:357–65.
113. Nishigami T, Karaoka TR, Ikeuchi H, et al. Adenocarcinomas associated with perianal fi stu-
lae in Crohn’s disease have a rectal, not an anal, immunophenotype. Pathology. 2011; 43(1):36–9.
114. Kulaylat MN, Doerr RJ, Karamanoukian H, et al. Basal cell carcinoma arising in fi stula-in-
ano. Am Surg. 1996;62(12):1000–2.
115. Baars JE, Kuipers EJ, Dijkstra G, et al. Malignant transformation of perianal and enterocuta-
neous fi stulas is rare: results of 17 years of follow-up from The Netherlands. Scand J Gastroenterol. 2011;46(3):319–25.
116. Ky A, Sohn N, Weinstein MA, et al. Carcinoma arising in anorectal fi stula of Crohn’s disease.
Dis Colon Rectum. 1998;41(8):992–6.
117. Millar DM. Villous neoplasms in anorectal fi stulas. Proctology. 1979;2:50.
118. Fincato M, Corsi C, Perrone A, et al. Perianal fi stulous abscesses and cloacogenic cancer.
Proctology. 1980;2:105.
119. Getz Jr SB, Ough YD, Patterson RB, et al. Mucinous adenocarcinoma developing in chronic
anal fi stula: report of two cases and review of the literature. Dis Colon Rectum. 1981;24(7): 562–6.
M. Luchtefeld and T. Jalouta

Pruritus Ani

Ursula M. Szmulowicz
Derived from Latin, pruritus ani refers to perianal and anal itching. Itching is a sensation that causes an impulsion to scratch. Primarily mediated by histamine, itch results from irritation of the unmyelinated C fi bers that end in the dermal-epidermal junction [ 1 ]. The incidence of pruritus ani ranges from 1 to 5 % [ 2 , 3 ]. In a popula- tion study in Joliet, Illinois, of 102 randomly selected participants, 6 % reported anal itching in the past year [ 4 ]. In contrast, Keighley and Williams reported a 45 % incidence of pruritus ani within the past 5 years when surveying patients without gastrointestinal complaints seen in a hospital outpatient department [ 5 , 6 ]. Due to the embarrassing nature of the complaint, the incidence may be greater than stated. Males suffer from pruritus ani more frequently than females, with a ratio of 2:1 to 4:1 [ 2 , 7 , 8 ]. Although the symptom may arise at any age, it is most common in the 40s to 60s [ 2 ]. In the series of 200 patients with pruritus ani from Bowyer and McColl, the majority of their patients presented in their middle 40s, with a range of 12–76 years old [ 7 ]. Perianal itching usually is a transient, self-limited symptom, resolving without any medical intervention. However, in a subset of patients, pruri­tus ani may be chronic, even becoming debilitating. Bowyer and McColl reported that 40 % of their patients had experienced perianal itching for 5 years or longer [ 7 ]. Five patients (7 %) in the series from Smith and colleagues experienced pruritus ani for more than 30 years [ 9 ].
Perianal itching arises from a myriad of etiologies (Table 7.1 ). Siddiqui and col- leagues comment that there are almost 100 discrete causes of pruritus ani [ 2 ]. Pruritus ani usually is due to a benign condition. The majority of patients are cate­gorized with idiopathic pruritus ani, in which, after a suitable assessment, no evi­dent cause for itching is found. The incidence of idiopathic pruritus ani varies among studies, from 25 to 75–95 % [ 8 , 10 , 11 ]. The secondary causes of pruritus ani
7
U. M. Szmulowicz , MD (*) Retired Staff Surgeon, Department of Colorectal Surgery , Cleveland Clinic , 9500 Euclid Ave , Cleveland , OH 44195 , USA
szmulou@gmail.com
e-mail:
© Springer International Publishing Switzerland 2016 M. Zutshi (ed.), Anorectal Disease, DOI 10.1007/978-3-319-23147-1_7
153
154
Table 7.1 Etiologies of pruritus ani
Idiopathic Fecal soilage
Dietary factors
Anorectal disease Abnormal anorectal morphology (congenital or postsurgical)
Anal fi ssure Fistula in ano Hypertrophic anal papilla Internal hemorrhoidal disease Perianal Crohn’s disease Rectal prolapse
Dermatologic conditions
Infection Bacterial: erythrasma and streptococcal and staphylococcal dermatitis
Neoplasia Anal cancer
Psychiatric disorders Anxiety
Systemic disease Celiac disease
Acanthosis nigricans Atopic dermatitis Benign familial chronic pemphigus (Hailey-Hailey disease) Contact dermatitis Lichen planus Lichen sclerosus Lichen simplex chronicus Psoriasis Seborrheic dermatitis Vitiligo
Fungal: candidiasis, dermatophytosis Parasitic: pediculosis, pinworms, scabies Sexually transmitted: chlamydia, condyloma (HPV), gonorrhea,
herpes, molluscum contagiosum, syphilis
Bowen’s disease (high-grade anal intra-epithelial neoplasia) Colon and rectal polyps and cancer Leukemia Lymphoma Perianal Paget’s disease
Depression Ekbom’s syndrome (parasitosis) Personality disorders
Diabetes mellitus Hyperthyroidism Infl ammatory bowel disease Iron-defi ciency anemia Liver disease Pellagra Polycythemia vera Renal disease/failure Vitamin A and D defi ciencies
U.M. Szmulowicz
7 Pruritus Ani
Fig. 7.1 Skin erythema and excoriation due to moisture/excessive wiping
include infectious, neoplastic, anal or colorectal, dermatologic, and psychiatric. A colonic or anorectal pathology is identifi ed in 75 % of patients with this com­plaint, including malignancies: rectal cancer (11 %), anal cancer (6 %), and colon cancer (2 %) in the review from Daniel and colleagues [ 2 , 8 ]. Anorectal disease, particularly internal hemorrhoidal disease, is present in as many as 52 % of patients with pruritus ani [ 2 ] (Fig. 7.1 ). Also, multiple pathologies may be present in a single patient: Bowyer and McColl diagnosed 257 conditions causing pruritus ani in their 200 patients, with one patient demonstrating fi ve discrete pathologies, all of which required treatment in order to effect a cure [ 7 ].
The nature of the disorder makes treatment challenging. Patients are reluctant to present to a physician with this sensitive, socially embarrassing complaint as well as to engage in a thorough discussion of the problem. Since, in many cases, treat­ment relies on lifestyle alterations such as diet and cleansing changes, patients may be disinclined to adhere to the physician’s recommendations. Moreover, pruritus ani may require the input of multiple specialists, primarily a colon and rectal surgeon and a dermatologist, for effective management. Surgeons, in particular, are often not interested in this chronic condition that often does not require surgical interven­tion and tends to feature multiple recurrences. Additionally, there are few studies to provide appropriate evidence-based strategies for treatment of the condition.
The following cases are presented to highlight the assessment and management of idiopathic pruritus ani as well as selected secondary causes of perianal itching (Fig. 7.2 ). Despite the source of the perianal pruritus, the goal of management is the resolution of itching and the reversal of any associated skin changes.
155

7.1 Case 1

The patient is a 45-year-old female who presents to your offi ce with the complaint of perianal itching. The assessment of the complaint of pruritus ani begins with a thorough history. The eventual successful treatment of the condition will be facili­tated by carefully listening to the patient at the initial visit to investigate his or her symptomology. When did the condition arise? Patients with pruritus ani due to a
156
U.M. Szmulowicz
Suspect idiopathic pruritus ani
Eliminate irritants
Diet change and stool bulking.
Control of itching.
Add barrier cream. Consider empiric pinworm treatment.
Add topical medication
Reassess for secondary causes of pruritus ani.
Benign anorectal disease
Medical or surgical treatment
Partial or no response
Partial or no response
No response
History and Physical Examination (perianal exam, DRE, anoscopy)
Perianal dermatosis
Full skin exam.
Skin biopsy.
Dermatology
consult.
Consider skin patch testing
Systemic Neoplasm
Medical treatment
Alarm symptoms
Consider blood work, colonoscopy, skin biopsy.
Full staging work up.
Appropriate surgical management.
Consider oncology or radition oncology referral.
Suspect infection
Skin scrapings.
Check for STIs.
Wood’s light exam.
Dermatology consult.
Consider methylene blue injection
Fig. 7.2 Algorithm for the management of pruritus ani
dermatosis or neoplasia often experience symptoms for longer than those with idio­pathic pruritus ani [ 8 ]. How often does the patient feel the perianal itching? Is it constantly present or does it ultimately subside? The precipitating and/or exacerbat­ing factors—especially the initial inciting event—for pruritus should be explored. In general, perianal itching usually develops following a bowel movement, particu­larly if it has a liquid consistency, or at bedtime [ 12 ]. Does the itching wake the